Date: 2018-09-12
Type of information: Nomination
Compound: chief scientific officer (CSO)
Company: Imcheck Therapeutics (France)
Therapeutic area: Cancer - Oncology - Autoimmune diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 12, 2018, ImCheck Therapeutics announced the appointment of René Hoet, PhD, as its Chief Scientific Officer. René Hoet is a molecular immunologist with over 20 years’ experience in antibody discovery and development. Over the course of his career, he has held leadership positions in antibody discovery and development at Bayer, Genmab, and Dyax.
- Before joining ImCheck, René spent 8 years at Bayer as Vice President Biologics Research, where his team was responsible for antibody lead discovery and optimization. Between 2008-2010, he was a member of the management team at Genmab and as Sr. Director Research led the team Product Related Research, Scientific Communication & Translational Research. Together with his team, he ran the antibody discovery programs and actively supported Genmab’s clinical antibody programs.
- René started his industrial career at Target Quest (acquired by Dyax in 1999) where his last position was Vice President Research and Operational Manager of Dyax. He was the driving force for internal antibody lead discovery as well as external collaborations and supported the out-licensing of Dyax’ antibody phage libraries. From these libraries, 3 antibodies have been approved by the FDA & EMA and over 10 antibodies from varies companies are currently in clinical trials.
- René Hoet is also Professor Biopharmaceutics at the University of Maastricht, Netherlands, guiding researchers to use antibodies to bridge the gap between academic research and pharmaceutical applications.
Financial terms:
Latest news:
Is general: Yes
